Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 2293

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 14
Chunk 2293
---
 
    $(7,955,338) 
    $(7,380,793)

    Net loss per common share - basic and diluted 
    $(1.43) 
    $(5.78)

    Weighted average number of common shares outstanding during the year - basic and diluted 
     5,574,473  
     1,276,543 

The
accompanying notes are an integral part of these consolidated financial statements.

F-4 

CHANNEL
THERAPEUTICS CORP

CONSOLIDATED
STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR
THE YEARS ENDED DECEMBER 31, 2024 AND 2023

    Preferred A Shares  
    Preferred A Shares Par  
    Preferred C Shares  
    Preferred C Shares Par  
    Common Shares  
    Par  
    Additional Paid-in Capital  
    Accumulated Deficit  
    Total Stockholders’ Deficit 

    Balance, December 31, 2022 
     600,000  
    $60  
     —  
    $—  
     1,111,112  
    $111  
    $2,432,148  
    $(6,138,856) 
    $(3,706,537)

    Stock-based compensation 
     —  
     —  
     —  
     —  
     —  
     —  
     1,733,233  
     —  
     1,733,233 

    Shares issued for extension of bridge loan 
     —  
     —  
     —  
     —  
     18,892  
     2  
     428,398  
     —  
     428,400)

    Shares issued for license 
     —  
     —  
     —  
     —  
     384,226  
     38  
     2,225,695  
     —  
     2,225,733 

    Shares issued for cash 
     —  
     —  
     —  
     —  
     2,525,815  
     253  
     255,159  
     —  
     255,